Skip to main content
. 2022 Apr 1;132(7):e153247. doi: 10.1172/JCI153247

Figure 6. IL-9 signaling deficiency impairs the longevity and antitumor effects of Tc9 cells.

Figure 6

Thy1.1+ Pmel-1 Tc9 cells from WT mice, Il9–/– mice, and Il9r–/– mice were injected into B16 tumor–bearing Thy1.2+ B6 mice with adjuvant treatments. (A) Relative lipid ROS, (B) iron level, (C) TMRM intensity, and (D) Thy1.1+ percentages in CD8+ T cells and Thy1.1+ CD8+ T cell numbers in tumors on day 45 after tumor injection (n = 6, two pooled independent experiments). (E and F) Tumor growth and survival curve of treated mice (n = 5). Data are presented as mean ± SEM. Eto, etomoxir; OE, overexpressing. *P < 0.05; **P < 0.01; ***P < 0.001 by log-rank (Mantel-Cox) test in F, 2-way ANOVA in E, and 1-way ANOVA followed by Dunnett’s test in the other panels.